Market Extra: Correction in Tesla, Netflix shares could last several weeks, stock charts warn
The stocks of both Tesla and Netflix fell into correction territory Friday, and charts suggest the selloffs could continue for as long as several weeks.
TaxWatch: Elderly couple was swindled out of $2 million by daughter — now they have to pay taxes on the stolen money
Congress eliminated the theft-loss deduction for defrauded taxpayers beginning in 2018. Tax attorneys want this protection restored.
Market Extra: These stock watchers nailed the market’s melt-up, but now they’re bracing for a fall. Here’s what to watch.
U.S. stocks are enjoying a breathtaking march higher despite some obvious headwinds. But that streak of winds could come crashing down.
: ‘Children fell in love with her immediately.’ How Barbie changed through the decades, from the icon’s 90-year-old designer
Barbie designer Carol Spencer was a visionary behind Mattel's icon from 1963 to 1998. She talks about careers — hers and Barbie's — and that...
Space Force raises the stakes as rocket companies compete for lucrative military missions
The U.S. military plans to buy even more rocket launches from companies in the coming years than previously expected.
: AMC stock surges 60% after Delaware judge puts brakes on APE-to-stock conversion plan
The stock of AMC Entertainment Holdings Inc. rocketed more than 60% higher after hours on Friday as judge makes a surprise ruling on special stock...
: Private-equity mogul Leon Black agreed to pay $62.5 million to settle Epstein-related claims: report
Leon Black agreed to pay $62.5 million to the Virgin Islands to be free from potential claims arising from a probe of sex-trafficking crimes by...
The Human Cost: Lukas Gage’s viral video audition haunts the ‘hot labor summer’ actors’ strike sweeping Hollywood
“These poor people who live in these tiny apartments,” an unmuted producer said on a Zoom call with the "White Lotus" actor.
: Gilead ends late-stage trial of blood cancer treatment
Shares of Gilead Sciences Inc. GILD dropped nearly 2% in the extended session Friday after the pharma company said it has ended a late-stage trial...